Biologics may reduce work & activity impairment in axial spondyloarthritis patients, study shows: 4 things to know

Written by Shayna Korol | August 21, 2018 | Print  |

Axial spondyloarthritis patients who received biologics-based treatment had less work and activity impairment than patients who did not receive biologics, according to a study in the Annals of the Rheumatic Diseases.

Here are four things to know:

1. The study included patients from across 83 U.K centers through the British Society for Rheumatology Biologics Register.

2. Around 27.9 percent of the 577 patients who were employed began biologic treatment at the time researchers sought out participants. At 12-month follow-up, patients receiving biologics demonstrated significantly greater improvements in overall work and activity impairment than patients who did not receive biologics.

3. Patients in both groups experienced no difference in absenteeism.

4. Researchers conducted a meta-analysis of 1,109 axSpA patients, which found biologics treatment correlated with work and activity impairment improvements. There was also no difference in absenteeism.

More articles on biologics:
Vericel appoints CMO: 3 details
17 key players in the global spine biologics market
Paragon 28 launches bone graft harvesting system for foot and ankle: 4 insights

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months